Fellowship · Orange, CA
Sponsored by University of California (Irvine)
Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study.
The Lancet. Neurology · 2023 · 231 citations · Ali Habib
Single-nucleus chromatin accessibility and transcriptomic characterization of Alzheimer's disease.
Nature genetics · 2021 · 537 citations · Mari Perez-Rosendahl
Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study.
The Lancet. Neurology · 2023 · 236 citations · Tahseen Mozaffar
Trial of Intravenous Immune Globulin in Dermatomyositis.
The New England journal of medicine · 2022 · 163 citations · Namita Goyal
Spatial and single-nucleus transcriptomic analysis of genetic and sporadic forms of Alzheimer's disease.
Nature genetics · 2024 · 98 citations · Mari Perez-Rosendahl
Single-cell and spatial transcriptomics identify a macrophage population associated with skeletal muscle fibrosis.
Science advances · 2023 · 121 citations · Tahseen Mozaffar
Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial.
The Lancet. Neurology · 2021 · 153 citations · Tahseen Mozaffar
Safety and efficacy of satralizumab in patients with generalised myasthenia gravis (LUMINESCE): a randomised, double-blind, multicentre, placebo-controlled phase 3 trial.
The Lancet. Neurology · 2025 · 30 citations · Ali Habib